Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random
- 1 December 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 840-841
Abstract
Linked Article: Nikolaou et al. Br J Dermatol 2022; 187:962–969.Keywords
This publication has 6 references indexed in Scilit:
- Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer PatientsBritish Journal of Dermatology, 2022
- Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancerInternational Journal of Dermatology, 2019
- Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor TherapyJAMA Dermatology, 2018
- Dermatologic Reactions to Immune Checkpoint InhibitorsAmerican Journal of Clinical Dermatology, 2017
- Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitorJournal of the European Academy of Dermatology and Venereology, 2017
- Development of bullous pemphigoid during nivolumab therapyJAAD Case Reports, 2016